Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
- \9 @6 a7 |/ |% W
' V) C7 X6 y$ l/ ~% v" y, _- z3 p1 _6 f: }
Sub-category:9 T7 i0 `& {/ l; ]7 P) ?$ ?
Molecular Targets ( e* b* `% R$ t; _# O
|4 `: P' I9 R. k, E- r
$ g% ]% |# D. KCategory:) X, n' V+ y% j L1 [
Tumor Biology " n( h* D$ ]& @+ t! `+ K! W
" N+ S; W b; L" ]/ C$ \! C
( H8 v# }" H1 F8 D8 M! `6 C
Meeting:& t+ q7 r! a4 S' }- a% ^
2011 ASCO Annual Meeting
5 W$ J4 X: \, h9 u' d
5 W$ o( }& |- f
5 z* w, j0 F5 V @$ I- MSession Type and Session Title:
z$ N. P1 [5 t' gPoster Discussion Session, Tumor Biology
+ x U: n* N& b# m: |7 _3 i
% Z* y; `, q$ I" L+ i% X, i t$ }: S7 G, Z+ M o9 w' C
Abstract No:
0 f- e9 p% p9 g+ v+ W5 r: v+ q10517 ( a" Z- W u- e" ], P
6 g/ q! L% X. w- C9 y2 N9 w$ s5 N
4 ~1 S6 Z2 r; w! CCitation:8 r/ I% B; y% @" c3 l8 R, G
J Clin Oncol 29: 2011 (suppl; abstr 10517)
) B; x: J0 z0 v$ {* L( t; p% P8 o2 k, l, ~) \. j; h& u
$ Z* ^! k* K2 }) p
Author(s):5 | ?8 \+ m# s$ U7 W
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
: d! k7 s2 @4 |! p; h0 b# n( U
# A" ?" P: q8 v% y- l
) |1 p P. e, i
2 I% o) }* u6 n; o2 U0 `Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
7 A L# q: [' m
: f4 F; J a5 QAbstract Disclosures
7 X# A& W/ F0 I/ W
" U; f% C3 N, i, N5 O1 {Abstract:
5 A: m) h3 x8 Y a8 H0 ^3 j5 N2 K6 x. M) }: Z8 U
( w; q0 V) a: n9 q. Q' s
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.! E1 B, }( Q# W. I) D
' Q9 M9 O# p9 ^% p5 ?0 _% ]
( B, n; T" h- o! e* H4 `
|
/ t% q3 Y- C7 {! M
显身卡
